The upcoming patent expiry of semaglutide on March 20 in India is paving the way for a surge in affordable generic versions. This milestone is expected to dismantle the monopoly of multinational pharmaceutical giants and democratize access to advanced weight-loss therapies.
A surge of competition from generic alternatives India’s $60 billion pharmaceutical industry is poised to capture billions in revenue by leveraging its strengths in generic manufacturing. Analysts predict:
-
Rapid market entry: Approximately 50 branded generic versions of semaglutide are expected to enter the market within a few months.
-
Cost optimization: Prices could drop by more than half compared to original products, making these treatments accessible beyond the wealthy demographic.
-
Market potential: The domestic semaglutide market in India could reach a valuation of $1 billion with the right pricing and consumption levels.
Mechanism of action and industry outlook Semaglutide belongs to the GLP-1 receptor agonist class, which mimics hormones that regulate appetite and blood sugar. By stimulating insulin release and slowing gastric emptying, these drugs have revolutionized weight management by helping users feel full faster and longer.
The launch of low-cost Indian versions is set to satisfy massive domestic demand and establish a foundation for future international supply. With a strategic goal to double its pharmaceutical sector by 2030, India is positioning itself as the global hub for effective and economical weight-loss solutions.
Source: https://thegioitiepthi.danviet.vn/thuoc-giam-can-gia-re-an-do-se-dinh-hinh-lai-thi-truong-toan-cau-thu-ve-hang-ty-usd-cho-nganh-duoc-d1411289.html